799 related articles for article (PubMed ID: 16160167)
1. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
[TBL] [Abstract][Full Text] [Related]
2. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
[TBL] [Abstract][Full Text] [Related]
3. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of and immunity to avian influenza A H5 viruses.
Katz JM; Lu X; Frace AM; Morken T; Zaki SR; Tumpey TM
Biomed Pharmacother; 2000 May; 54(4):178-87. PubMed ID: 10872716
[TBL] [Abstract][Full Text] [Related]
5. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
[TBL] [Abstract][Full Text] [Related]
6. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
Ninomiya A; Imai M; Tashiro M; Odagiri T
Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
[TBL] [Abstract][Full Text] [Related]
7. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
[TBL] [Abstract][Full Text] [Related]
8. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
9. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.
Horimoto T; Takada A; Iwatsuki-Horimoto K; Kawaoka Y
Vaccine; 2004 Jun; 22(17-18):2244-7. PubMed ID: 15149783
[TBL] [Abstract][Full Text] [Related]
10. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Brett IC; Johansson BE
Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
[TBL] [Abstract][Full Text] [Related]
11. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
[TBL] [Abstract][Full Text] [Related]
12. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
Qiu M; Fang F; Chen Y; Wang H; Chen Q; Chang H; Wang F; Wang H; Zhang R; Chen Z
Biochem Biophys Res Commun; 2006 May; 343(4):1124-31. PubMed ID: 16580631
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
[TBL] [Abstract][Full Text] [Related]
14. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
15. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
[TBL] [Abstract][Full Text] [Related]
16. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
[TBL] [Abstract][Full Text] [Related]
17. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
[TBL] [Abstract][Full Text] [Related]
18. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
[TBL] [Abstract][Full Text] [Related]
19. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine.
Gabriel G; Garn H; Wegmann M; Renz H; Herwig A; Klenk HD; Stech J
Vaccine; 2008 Feb; 26(7):956-65. PubMed ID: 18164519
[TBL] [Abstract][Full Text] [Related]
20. A vaccine prepared from a non-pathogenic H7N7 virus isolated from natural reservoir conferred protective immunity against the challenge with lethal dose of highly pathogenic avian influenza virus in chickens.
Sakabe S; Sakoda Y; Haraguchi Y; Isoda N; Soda K; Takakuwa H; Saijo K; Sawata A; Kume K; Hagiwara J; Tuchiya K; Lin Z; Sakamoto R; Imamura T; Sasaki T; Kokumai N; Kawaoka Y; Kida H
Vaccine; 2008 Apr; 26(17):2127-34. PubMed ID: 18346824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
